Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

2 years ago

SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has…

Rhythm Pharmaceuticals Presents New Data at ESPE 2023

2 years ago

BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference

2 years ago

CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving…

An Unforgettable Evening at Westmount Public Library Draws Rave Reviews

2 years ago

TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- On the evening of September 19, 2023, the Fatty Liver Alliance, a Canadian…

Synapse Dental Completes Equity Financing Round with Backing From AAO Innovation & Transformation Fund

2 years ago

CRANSTON, R.I., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Synapse Dental, the maker of the Dental Pain EraserTM, announced the completion…

TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

2 years ago

Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ETNEW YORK, Sept. 22, 2023 (GLOBE NEWSWIRE) -- TG…

Mithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d’une conférence web le 26 septembre à 14 h 00 CET

2 years ago

Mithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d'une conférence web le 26 septembre à 14…

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

2 years ago

TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF),…

PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

2 years ago

PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming…

ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress

2 years ago

SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company…